202 related articles for article (PubMed ID: 31213350)
1. Cardiovascular manifestations of myotonic dystrophy.
Wahbi K; Furling D
Trends Cardiovasc Med; 2020 May; 30(4):232-238. PubMed ID: 31213350
[TBL] [Abstract][Full Text] [Related]
2. Patients upgraded to cardiac resynchronization therapy due to pacing-induced cardiomyopathy are at low risk of life-threatening ventricular arrhythmias: a long-term cause-of-death analysis.
Barra S; Duehmke R; Providencia R; Marijon E; Boveda S; Virdee M; Heck P; Fynn S; Begley D; Grace A; Agarwal S
Europace; 2018 Jan; 20(1):89-96. PubMed ID: 28031276
[TBL] [Abstract][Full Text] [Related]
3. A 10-year follow-up of a patient affected by myotonic dystrophy type 1 with implantable cardioverter-defibrillator implanted for secondary prevention.
De Ambroggi G; Ali H; Cappato R; Sansone VA; De Ambroggi L
J Cardiovasc Med (Hagerstown); 2020 Feb; 21(2):150-152. PubMed ID: 31490228
[No Abstract] [Full Text] [Related]
4. Implantable cardiac electronic device therapy for patients with a systemic right ventricle.
Barracano R; Brida M; Guarguagli S; Palmieri R; Diller GP; Gatzoulis MA; Wong T
Heart; 2020 Jul; 106(14):1052-1058. PubMed ID: 32269130
[TBL] [Abstract][Full Text] [Related]
5. Cardiac implantable electronic device and vascular access: Strategies to overcome problems.
Kusztal M; Nowak K
J Vasc Access; 2018 Nov; 19(6):521-527. PubMed ID: 29552930
[TBL] [Abstract][Full Text] [Related]
6. Twenty-four-hour ambulatory ECG monitoring relevancy in myotonic dystrophy type 1 follow-up: Prognostic value and heart rate variability evolution.
Gamet A; Degand B; Le Gal F; Bidegain N; Delaubier A; Gilbert-Dussardier B; Christiaens L; Garcia R
Ann Noninvasive Electrocardiol; 2019 Jan; 24(1):e12587. PubMed ID: 30101452
[TBL] [Abstract][Full Text] [Related]
7. Cardiac Conduction Disorders as Markers of Cardiac Events in Myotonic Dystrophy Type 1.
Itoh H; Hisamatsu T; Tamura T; Segawa K; Takahashi T; Takada H; Kuru S; Wada C; Suzuki M; Suwazono S; Sasaki S; Okumura K; Horie M; Takahashi MP; Matumura T
J Am Heart Assoc; 2020 Sep; 9(17):e015709. PubMed ID: 32812471
[TBL] [Abstract][Full Text] [Related]
8. End-of-life of implantable defibrillator: are we certain it should always be replaced?
Stazi F
J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e116-e119. PubMed ID: 29538158
[No Abstract] [Full Text] [Related]
9. Electrocardiographic risk stratification in patients with a primary prophylactic implantable cardioverter defibrillator: can future arrhythmias correlating with sudden cardiac death be predicted?
Zabel M; Friede T
Europace; 2024 Jun; 26(6):. PubMed ID: 38758091
[TBL] [Abstract][Full Text] [Related]
10. Ongoing Risk of Ventricular Arrhythmias and All-Cause Mortality at Implantable Cardioverter Defibrillator Generator Change: A Systematic Review and Meta-Analysis.
Yuyun MF; Erqou SA; Peralta AO; Hoffmeister PS; Yarmohammadi H; Echouffo-Tcheugui JB; Martin DT; Joseph J; Singh JP
Circ Arrhythm Electrophysiol; 2021 Mar; 14(3):e009139. PubMed ID: 33554611
[TBL] [Abstract][Full Text] [Related]
11. The wearable cardioverter-defibrillator: current technology and evolving indications.
Reek S; Burri H; Roberts PR; Perings C; Epstein AE; Klein HU; ; Lip G; Gorenek B; Sticherling C; Fauchier L; Goette A; Jung W; Vos MA; Brignole M; Elsner C; Dan GA; Marin F; Boriani G; Lane D; Blomström-Lundqvist C; Savelieva I
Europace; 2017 Mar; 19(3):335-345. PubMed ID: 27702851
[TBL] [Abstract][Full Text] [Related]
12. Prevention of Sudden Cardiac Death: Focus on the Subcutaneous Implantable Cardioverter-Defibrillator.
Adduci C; Palano F; Silvetti G; Cosentino P; Francia P
High Blood Press Cardiovasc Prev; 2020 Aug; 27(4):291-297. PubMed ID: 32519207
[TBL] [Abstract][Full Text] [Related]
13. Predictors of atrio-ventricular conduction disease, long-term outcomes in patients with myotonic dystrophy types I and II.
Ha AH; Tarnopolsky MA; Bergstra TG; Nair GM; Al-Qubbany A; Healey JS
Pacing Clin Electrophysiol; 2012 Oct; 35(10):1262-9. PubMed ID: 22385162
[TBL] [Abstract][Full Text] [Related]
14. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC).
Priori SG; Blomström-Lundqvist C; Mazzanti A; Blom N; Borggrefe M; Camm J; Elliott PM; Fitzsimons D; Hatala R; Hindricks G; Kirchhof P; Kjeldsen K; Kuck KH; Hernandez-Madrid A; Nikolaou N; Norekvål TM; Spaulding C; Van Veldhuisen DJ;
Europace; 2015 Nov; 17(11):1601-87. PubMed ID: 26318695
[No Abstract] [Full Text] [Related]
15. Long-term arrhythmia follow-up of patients with myotonic dystrophy.
Benhayon D; Lugo R; Patel R; Carballeira L; Elman L; Cooper JM
J Cardiovasc Electrophysiol; 2015 Mar; 26(3):305-10. PubMed ID: 25546341
[TBL] [Abstract][Full Text] [Related]
16. Mortality Implications of Appropriate Implantable Cardioverter Defibrillator Therapy in Secondary Prevention Patients: Contrasting Mortality in Primary Prevention Patients From a Prospective Population-Based Registry.
Almehmadi F; Porta-Sánchez A; Ha ACT; Fischer HD; Wang X; Austin PC; Lee DS; Nanthakumar K
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862957
[TBL] [Abstract][Full Text] [Related]
17. Incidence, indications, risk factors, and survival of patients undergoing cardiac implantable electronic device implantation after open heart surgery.
Wiggins NB; Chong DT; Houghtaling PL; Hussein AA; Saliba W; Sabik JF; Wazni O; Wilkoff BL; Tarakji KG
Europace; 2017 Aug; 19(8):1335-1342. PubMed ID: 27738074
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous implantable cardioverter defibrillator indication in prevention of sudden cardiac death in difficult clinical situations: A French expert position paper.
Probst V; Boveda S; Sadoul N; Marquié C; Chauvin M; Mondoly P; Gras D; Jacon P; Defaye P; Leclercq C; Anselme F
Arch Cardiovasc Dis; 2020 May; 113(5):359-366. PubMed ID: 32334981
[TBL] [Abstract][Full Text] [Related]
19. Eligibility of Pacemaker Patients for Subcutaneous Implantable Cardioverter Defibrillators.
Ip JE; Wu MS; Kennel PJ; Thomas G; Liu CF; Cheung JW; Markowitz SM; Lerman BB
J Cardiovasc Electrophysiol; 2017 May; 28(5):544-548. PubMed ID: 28185354
[TBL] [Abstract][Full Text] [Related]
20. Does cytosine-thymine-guanine (CTG) expansion size predict cardiac events and electrocardiographic progression in myotonic dystrophy?
Clarke NR; Kelion AD; Nixon J; Hilton-Jones D; Forfar JC
Heart; 2001 Oct; 86(4):411-6. PubMed ID: 11559681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
